CERVICAL ADENOCARCINOMA
Clinical trials for CERVICAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new CERVICAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for CERVICAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Three-Drug attack on Tough-to-Treat cervical cancer
Disease control Recruiting nowThis study is testing a new combination of three drugs for women with a rare and aggressive type of cervical cancer that has spread, come back, or did not respond to prior treatment. The goal is to see if adding a new oral drug (IN10018) to two existing intravenous drugs can bett…
Matched conditions: CERVICAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Apr 04, 2026 03:20 UTC
-
Experimental cancer drug enters human testing for Tough-to-Treat tumors
Disease control Recruiting nowThis is the first human study of an experimental cancer drug called AVA6103. It's being tested in adults with advanced solid tumors that have spread or can't be surgically removed, including pancreatic, lung, gastric, and cervical cancers. The trial aims to find the safest dose a…
Matched conditions: CERVICAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Avacta Life Sciences Ltd • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New 'Tumor-Seeking' radiation drug enters human trials for tough cancers
Disease control Recruiting nowThis study is testing a new type of cancer drug that delivers radiation directly to tumors by targeting a protein called Nectin-4. It aims to find a safe and effective dose for patients with advanced solid cancers who have already tried other treatments. The trial will first dete…
Matched conditions: CERVICAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Aktis Oncology, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC